Document is current
Any future updates will be listed below
-
Authors
Cheng, Mingbo https://orcid.org/0000-0003-3938-0461
Jansen, Jitske
Reimer, Katharina C. https://orcid.org/0000-0002-7118-9133
Grande, Vincent P.
Nagai, James S. https://orcid.org/0000-0002-7655-7206
Li, Zhijian https://orcid.org/0000-0002-1523-1333
Kießling, Paul https://orcid.org/0000-0002-9794-9532
Grasshoff, Martin
Kuppe, Christoph https://orcid.org/0000-0003-4597-9833
Schaub, Michael T. https://orcid.org/0000-0003-2426-6404
Kramann, Rafael https://orcid.org/0000-0003-4048-6351
Costa, Ivan G. https://orcid.org/0000-0003-2890-8697
- License Information
-
More Information
Article History
Received: 30 September 2024
Accepted: 17 September 2025
First Online: 23 October 2025
Competing interests
: R.K. is founder and board member of Sequantrix, is a member of the scientific advisory board of Hybridize Therapeutics, received honoraria from Bayer, Chugai, Pfizer, Roche, Genentech, Lilly and GSK, and received research funding from Travere Therapeutics, Galapagos, Novo Nordisk and Ask Bio. The other authors declare no competing interests.
